

- National Center for Complementary and Alternative Medicine. What is Complementary and Alternative Medicine? NCCAM Publication D347 2010. <http://nccam.nih.gov/health/whatiscam/>. Accessed on (date).
- Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. *JAMA* 1998;280:1569–1575.
- Dietary Supplement Health and Education Act of 1994 (DSHEA). Public Law 103–417, U.S. Congress (October 25, 1994).
- Astin JA. Why patients use alternative medicine: results of a national study. *JAMA* 1998;279:1548–1553.
- Druss BG, Rosenheck RA. Association between use of unconventional therapies and conventional medical services. *JAMA* 1999;282:651–656.
- Wolsko PM, Eisenberg DM, Davis RB, et al. Insurance coverage, medical conditions, and visits to alternative medicine providers: results of a national survey. *Arch Intern Med* 2002;162:281–287.
- Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. *Natl Health Stat Rep* 2008;12:1–23.
- Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. *J Clin Oncol* 2000;18:2505–2514.
- Adler SR, Fosket JR. Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. *J Fam Pract* 1999;48:453–458.
- Bernstein BJ, Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. *Oncology (Williston Park)* 2001;15:1267–1272.
- Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. *N Engl J Med* 1999;340:1733–1739.
- Gotay CC, Hara W, Issell BF, et al. Use of complementary and alternative medicine in Hawaii cancer patients. *Hawaii Med J* 1999;58:94–98.
- Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. *Cancer* 2000;88:615–619.
- Lee MM, Chang JS, Jacobs B, et al. Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations. *Am J Public Health* 2002;92:1606–1609.
- Lippert MC, McClain R, Boyd JC, et al. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. *Cancer* 1999;86:2642–2648.
- Maskarinec G, Shumay DM, Kakai H, et al. Ethnic differences in complementary and alternative medicine use among cancer patients. *J Altern Complement Med* 2000;6:531–538.
- Morris KT, Johnson N, Homer L, et al. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. *Am J Surg* 2000;179:407–411.
- Patterson RE, Neuhouser ML, Hedderson MM, et al. Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. *J Altern Complement Med* 2002;8:477–485.
- Shumay DM, Maskarinec G, Gotay CC, et al. Determinants of the degree of complementary and alternative medicine use among patients with cancer. *J Altern Complement Med* 2002;8:661–671.
- Sparber A, Bauer L, Curt G, et al. Use of complementary medicine by adult patients participating in cancer clinical trials. *Oncol Nurs Forum* 2000;27:623–630.
- Swisher EM, Cohn DE, Goff BA, et al. Use of complementary and alternative medicine among women with gynecologic cancers. *Gynecol Oncol* 2002;84:363–367.
- VandeCreek L, Rogers E, Lester J. Use of alternative therapies among breast cancer outpatients compared with the general population. *Altern Ther Health Med* 1999;5:71–76.
- White JD. The National Cancer Institute's perspective and agenda for promoting awareness and research on alternative therapies for cancer. *J Altern Complement Med* 2002;8:545–550.
- McEachrane-Gross FP, Liebschutz JM, Berlowitz D. Use of selected complementary and alternative medicine (CAM) treatments in veterans with cancer or chronic pain: a cross-sectional survey. *BMC Complement Altern Med* 2006;6:34.
- Swarup AB, Barrett W, Jazieh AR. The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. *Am J Clin Oncol* 2006;29:468–473.
- Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. *Cancer* 1998;83:777–782.
- Sparber A, Wooten JC. Surveys of complementary and alternative medicine: pt II. Use of alternative and complementary cancer therapies for children with cancer. *J Alt Comp Med* 2001;7:281–287.
- Friedman T, Slayton WB, Allen LS, et al. Use of alternative therapies for children with cancer. *Pediatrics* 1997;100:E1.
- Kelly KM, Jacobson JS, Kennedy DD, et al. Use of unconventional therapies by children with cancer at an urban medical center. *J Pediatr Hematol Oncol* 2000;22:412–416.
- McLean TW, Kemper KJ. Complementary and alternative medicine therapies in pediatric oncology patients. *J Soc Integr Oncol* 2006;4:40–45.
- Weyl BA, Geva H, Ofir R, et al. Prevalence and characteristics of complementary medicine used by pediatric cancer patients in a mixed Western and Middle-Eastern population. *J Pediatr Hematol Oncol* 2006;28:141–146.
- Paltiel O, Avitzour M, Peretz T, et al. Determinants of the use of complementary therapies by patients with cancer. *J Clin Oncol* 2001;19:2439–2448.
- Chen FP, Chen TJ, Kung YY, et al. Use frequency of traditional Chinese medicine in Taiwan. *BMC Health Serv Res* 2007;7:26.
- Fouladbakhsh JM, Stommel M, Given BA, Given CW. Predictors of use of complementary and alternative therapies among patients with cancer. *Oncol Nurs Forum* 2005;32:1115–1122.
- Gansler T, Kaw C, Crammer C, Smith T. A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society's studies of cancer survivors. *Cancer* 2008;113:1048–1057.
- Engel GL. The need for a new medical model: a challenge for biomedicine. *Science* 1977;196:129–136.
- Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol* 2006;71:1397–1421.
- Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. *J Natl Cancer Inst* 2006;98:1767–1776.
- Pierce JP, Natarajan L, Cuan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. *JAMA* 2007;298:289–298.
- Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. *J Clin Oncol* 2007;25:2345–2351.
- Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 9803. *J Clin Oncol* 2006;24:3535–3541.
- Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. *JAMA* 2007;298:754–764.
- Doyle C, Kushi LH, Byers T, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. *CA Cancer J Clin* 2006;56:323–353.
- Vickers AJ. Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. *J R Soc Med* 1996;89:303–311.
- Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. *J Clin Oncol* 2005;23:7188–7198.
- Lee A, Done ML. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: a meta-analysis. *Anesth Analg* 1999;88:1362–1369.
- Lee A, Done ML. Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. *Cochrane Database Syst Rev* 2004;3:CD003281.
- Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. *Proc Nutr Soc* 2008;67:253–256.
- Litton JK, Gonzalez-Angulo AM, Warneke CL, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. *J Clin Oncol* 2008;26:4072–4077.
- Li CI, Daling JR, Porter PL, et al. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. *J Clin Oncol* 2009;27:5312–5318.
- Adler NE, Page AEK, National Institute of Medicine. *Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs*. Washington, DC: National Academies Press; 2008.
- Shankar K, Liao LP. Traditional systems of medicine. *Phys Med Rehabil Clin North Am* 2004;15:725–747.
- Baum A, Singer JE. *Handbook of Psychology and Health*. Hillsdale, NJ: Erlbaum; 1987.
- Cohen L, Littlefield C, Kelly P, Maurer J, et al. Predictors of quality of life and adjustment after lung transplantation. *Chest* 1998;113:633–644.
- Grunberg NE, Baum A. Biological commonalities of stress and substance abuse. In: Shiffman S, Willis T, eds. *Coping and Substance Abuse*. Orlando: Academic Press; 1985:25–61.
- Ironson G, Wynings C, Schneiderman N, et al. Posttraumatic stress symptoms, intrusive thoughts, loss, and immune function after Hurricane Andrew. *Psychosom Med* 1997;59:128–141.
- Irvin M, Smith TL, Gillin JC. Electroencephalographic sleep and natural killer activity in depressed patients and control subjects. *Psychosom Med* 1992;54:10–21.
- Curry SJ, Emmons KM. Theoretical models for predicting and improving compliance with breast cancer screening. Mini-series: advances in behavioral medicine research on breast cancer. *Ann Behav Med* 1994;16:302.
- Lerman C, Daly M, Sands C, et al. Mammography adherence and psychological distress among women at risk for breast cancer. *J Natl Cancer Inst* 1993;85:1074–1080.

60. Baum A, Cohen L, Hall M. Control and intrusive memories as possible determinants of chronic stress. *Psychosom Med* 1993;55:274–286.
61. Light KC, Turner JR, Hinderliter AL, et al. Race and gender comparisons: I. Hemodynamic responses to a series of stressors. *Health Psychol* 1993;12:354–365.
62. Light KC, Kothandapani RV, Allen MT. Enhanced cardiovascular and catecholamine responses in women with depressive symptoms. *Int J Psychophysiol* 1998;28:157–166.
63. Patterson SM, Zakowski SC, Hall MH, et al. Psychological stress and platelet activation: differences in platelet reactivity in healthy men during active and passive stressors. *Health Psychol* 1994;13:34–38.
64. Schaeffer MA, Baum A. Adrenal cortical response to stress at Three Mile Island. *Psychosom Med* 1984;46:227–237.
65. Yehuda R, Resnick H, Kahana B, et al. Long-lasting hormonal alterations to extreme stress in humans: normative or maladaptive? *Psychosom Med* 1993;55:287–297.
66. Cohen S. Psychological stress, immunity, and upper respiratory infections. *Curr Dir Psychol Sci* 1996;5:86–89.
67. Glaser R, Kiecolt-Glaser JK, Speicher CE, et al. Stress, loneliness, and changes in herpesvirus latency. *J Behav Med* 1985;8:249–260.
68. Kiecolt-Glaser JK, Glaser R, Shuttlesworth EC, et al. Chronic stress and immunity in family caregivers of Alzheimer's disease victims. *Psychosom Med* 1987;49:523–535.
69. Kiecolt-Glaser JK, Marucha PT, Malarkey WB, et al. Slowing of wound healing by psychological stress. *Lancet* 1995;346:1194–1196.
70. Marucha PT, Kiecolt-Glaser JK, Favagehi M. Mucosal wound healing is impaired by examination stress. *Psychosom Med* 1998;60:362–365.
71. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. *Nat Rev Immunol* 2005;5:243–251.
72. Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. *Nat Rev Cancer* 2006;6:240–248.
73. Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. *J Clin Oncol* 2010;28:4094–4099.
74. Cunningham AJ, Edmonds CV, Jenkins GP, et al. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. *Psychooncology* 1998;7:508–517.
75. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. *N Engl J Med* 2001;345:1719–1726.
76. Spiegel D, Bloom JR, Kraemer HC, et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. *Lancet* 1989;2:888–891.
77. Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. *Cancer* 2007;110:1130–1138.
78. Andersen BL, Yang HC, Farrar WB, et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. *Cancer* 2008;113:3450–3458.
79. Guo Z, Tang HY, Li H, et al. The benefits of psychosocial interventions for cancer patients undergoing radiotherapy. *Health Qual Life Outcomes* 2013;11:121.
80. Navo MA, Phan J, Vaughan C, et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. *J Clin Oncol* 2004;22:671–677.
81. Ulbricht C, Chao W, Costa D, et al. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. *Curr Drug Metab* 2008;9:1063–1120.
82. Verhoef MJ, White MA, Doll R. Cancer patients' expectations of the role of family physicians in communication about complementary therapies. *Cancer Prev Control* 1999;3:181–187.
83. Berk LB. Primer on integrative oncology. *Hematol Oncol Clin North Am* 2006;20:213–231.
84. Robotin MC, Penman AG. Integrating complementary therapies into mainstream cancer care: which way forward? *Med J Aust* 2006;185:377–379.
85. Sugarman J, Burk L. Physicians' ethical obligations regarding alternative medicine. *JAMA* 1998;280:1623–1625.
86. Frenkel M, Ben Arye E, Baldwin CD, et al. Approach to communicating with patients about the use of nutritional supplements in cancer care. *South Med J* 2005;98:289–294.
87. Palmer ME, Haller C, McKinney PE, et al. Adverse events associated with dietary supplements: an observational study. *Lancet* 2003;361:101–106.
88. Fugh-Berman A. Herb-drug interactions. *Lancet* 2000;355:134–138.
89. Moss RW. Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? *Integr Cancer Ther* 2006;5:63–82.
90. Weiger WA, Smith M, Boon H, et al. Advising patients who seek complementary and alternative medical therapies for cancer. *Ann Intern Med* 2002;137:889–903.
91. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. *J Clin Pharm Ther* 2002;27:391–401.
92. Piscitelli SC, Burstein AH. Herb-drug interactions and confounding in clinical trials. *J Herb Pharmacother* 2002;2:23–26.
93. Ernst E. Possible interactions between synthetic and herbal medicinal products. pt 1: a systematic review of the indirect evidence. *Perfusion* 2000;13:4–15.
94. Ernst E. Interactions between synthetic and herbal medicinal products. Part 2: a systematic review of the direct evidence. *Perfusion* 2000;13:60–70.
95. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. *Drugs* 2001;61:2163–2175.
96. Hardy ML. Herb-drug interactions: an evidence-based table. *Alt Med Alert* 2000;6:64–69.
97. Lambrecht J, Rabinovich A, Hamilton W. A review of herb-drug interactions: documented and theoretical. *US Pharmacist* 2000;25:1–10.
98. Mathijssen RHJ, Verweij J, DeBruijn P. Modulation of irinotecan (CPT-11) metabolism by St. John's wort in cancer patients. Presented at: 93rd Annual Meeting of American Association for Cancer Research; April 6–10, 2002; San Francisco, CA.
99. Smith P, Bullock JM, Booker BM, et al. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. *Pharmacotherapy* 2004;24:1508–1514.
100. Prasad KN, Kumar A, Kochupillai V, et al. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. *J Am Coll Nutr* 1999;18:13–25.
101. Seifried HE, McDonald SS, Anderson DE, et al. The antioxidant conundrum in cancer. *Cancer Res* 2003;63:4295–3298.
102. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. *J Natl Cancer Inst* 2005;97:481–488.
103. Bairati I, Meyer F, Jobin E, et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. *Int J Cancer* 2006;119:2221–2224.
104. Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. *Cancer Treat Rev* 2007;33:407–418.
105. Lawenda BD, Kelly KM, Ladas EJ, et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? *J Natl Cancer Inst* 2008;100:773–783.
106. Lai MN, Lai JN, Chen PC, et al. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. *Am J Kidney Dis* 2010;55:507–518.
107. Frei E 3rd, Jaffe N, Tattersall MH, et al. New approaches to cancer chemotherapy with methotrexate. *N Engl J Med* 1975;292:846–851.
108. Zaineddin AK, Buck K, Vrieling A, et al. The association between dietary lignans, phytoestrogen-rich foods, and fiber intake and postmenopausal breast cancer risk: A German Case-Control Study. *Nutr Cancer* 2012;64:652–665.
109. Anderson LN, Cotterchio M, Boucher B, et al. Phytoestrogen intake from foods, during adolescence and adulthood, and risk of breast cancer by estrogen and progesterone receptor tumor subgroup among Ontario women. *Int J Cancer* 2013;132:1683–1692.
110. Reynolds T. Contamination of PC-SPES remains a mystery. *J Natl Cancer Inst* 2002;94:1266–1268.
111. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. *J Natl Cancer Inst* 1996;88:1550–1559.
112. Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: a systematic review and meta-analysis of randomized controlled trials. *Int J Cancer* 2010;127:172–184.
113. Cortes EP, Gupta M, Chou C, et al. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. *Cancer Treat Rep* 1978;62:887–891.
114. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Mol Aspects Med* 1994;15:207–212.
115. Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. *J Clin Pharmacol* 1990;30:596–608.
116. Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. *J Hum Hypertens* 1999;13:203–208.
117. Eriksson JG, Forsen TJ, Mortensen SA, et al. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. *Biofactors* 1999;9:315–318.
118. Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. *J Card Fail* 2006;12:464–472.
119. van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. *Cochrane Database Syst Rev* 2008;(2):CD003917.
120. Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. *Ugeskr Laeger* 1998;160:3226–3227.
121. Combs AB, Porter TH, Folkers K. Anticoagulant activity of a naphthoquinone analog of vitamin K and an inhibitor of coenzyme Q10-enzyme systems. *Res Commun Chem Pathol Pharmacol* 1976;13:109–114.
122. Spigset O. Reduced effect of warfarin caused by ubiquinolone. *Lancet* 1994;344:1372–1373.
123. Go P, Chung CH. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx. *J Int Med Res* 1989;17:141–149.
124. Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunotherapy with polysaccharide K for patients with curatively resected colorectal

- cancer: a meta-analysis of centrally randomized controlled clinical trials. *Cancer Immunol Immunother* 2006;55:404–411.
125. Oba K, Teramukai S, Kobayashi M, et al. Efficacy of adjuvant immunotherapy with polysaccharide K for patients with curative resections of gastric cancer. *Cancer Immunol Immunother* 2007;56:905–911.
 126. Sakamoto J, Teramukai S, Koike A, et al. Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunotherapy with PSK for Gastric Cancer. *Cancer* 1996;77:2206–2212.
 127. Yokoe T, Iino Y, Takei H, et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunotherapy with PSK. *Anticancer Res* 1997;17:2815–2818.
 128. Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomized trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACE/TBC) of Japan. *Eur J Cancer* 1996;32A:235–242.
 129. Iino Y, Yokoe T, Maemura M, et al. Immunotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. *Anticancer Res* 1995;15:2907–2911.
 130. Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. *Cancer* 1992;70:2475–2483.
 131. Ogoshi K. [Evaluation of immunotherapy with PSK in esophageal cancer]. *Gan To Kagaku Ryoho* 1988;15:3143–3151.
 132. Ogoshi K, Satou H, Isono K, et al. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. The Cooperative Study Group for Esophageal Cancer in Japan. *Cancer Invest* 1995;13:363–369.
 133. Ogoshi K, Satou H, Isono K, et al. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. *Am J Clin Oncol* 1995;18:216–222.
 134. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. *Cancer Detect Prev* 1997;21:71–77.
 135. Ikeda T, Sakai T, Suito T, et al. [Evaluation of postoperative immunotherapy in lung cancer]. *Gan To Kagaku Ryoho* 1986;13:1044–1049.
 136. Nishiwaki Y, Furuse K, Fukuoka M, et al. [A randomized controlled study of PSK combined immunotherapy for adenocarcinoma of the lung. The Advanced Lung Cancer Immuno-chemotherapy Study Group]. *Gan To Kagaku Ryoho* 1990;17:131–136.
 137. Suto T, Fukuda S, Moriya N, et al. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. *Cancer Chemother Pharmacol* 1994;33:S145–S148.
 138. Chung CH, Go P, Chang KH. PSK immunotherapy in cancer patients—a preliminary report. *Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi* 1987;20:210–216.
 139. Ohno R, Yamada K, Masaoka T, et al. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. *Cancer Immunol Immunother* 1984;18:149–154.
 140. Nagao T, Komatsuda M, Yamauchi K, et al. Chemoimmunotherapy with Krestin in acute leukemia. *Tokai J Exp Clin Med* 1981;6:141–146.
 141. Takahashi Y, Mai M, Nakazato H. Preoperative CEA and PPD values as prognostic factors for immunotherapy using PSK and 5-FU. *Anticancer Res* 2005;25:1377–1384.
 142. Fukuo Y, Terashi A, Hayashi Y, et al. [A clinical trial of cis-platinum (II) in combination with PSK and FT-207 in advanced stomach cancer]. *Gan To Kagaku Ryoho* 1985;12:960–965.
 143. Niimoto M, Hattori T, Tamada R, et al. Postoperative adjuvant immunotherapy with mitomycin C, fuafuafu and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. *Jpn J Surg* 1988;18:681–686.
 144. Tamada R, Inokuchi K, Hattori T, et al. [A multi-institutional study on postoperative adjuvant immunotherapy of gastric cancer (II)]. *Gan To Kagaku Ryoho* 1987;14:716–722.
 145. Hattori T, Niimoto M, Toge T, et al. Effects of levamisole in adjuvant immunotherapy for gastric cancer; a prospective randomized controlled study. *Jpn J Surg* 1983;13:480–485.
 146. Ito K, Nakazato H, Koike A, et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. *Int J Colorectal Dis* 2004;19:157–164.
 147. Munemoto Y, Iida Y, Abe J, et al. Significance of postoperative adjuvant immunotherapy after curative resection of colorectal cancers: association between host or tumor factors and survival. *Int J Oncol* 2002;20:403–411.
 148. Ogoshi K, Tajima T, Mitomi T, et al. HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer. *Cancer Immunol Immunother* 1997;45:53–59.
 149. Imaizumi M, Kondo T, Kamei H, et al. [Cooperative studies on surgical adjuvant immunotherapy for prevention of postoperative recurrence of gastric cancer]. *Gan To Kagaku Ryoho* 1984;11:60–68.
 150. Tsujitani S, Kakeji Y, Orita H, et al. Postoperative adjuvant immunotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. *Anticancer Res* 1992;12:645–648.
 151. Nakazato H, Koike A, Saji S, et al. Efficacy of immunotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunotherapy with PSK for Gastric Cancer. *Lancet* 1994;343:1122–1126.
 152. Kaegi E. Unconventional therapies for cancer. 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. *CMAJ* 1998;158:897–902.
 153. Bryer E. A literature review of the effectiveness of ginger in alleviating mild-to-moderate nausea and vomiting of pregnancy. *J Midwifery Womens Health* 2005;50:e1–e3.
 154. Chittumma P, Kaewkiattikun K, Wiriyasriwath B. Comparison of the effectiveness of ginger and vitamin B6 for treatment of nausea and vomiting in early pregnancy: a randomized double-blind controlled trial. *J Med Assoc Thai* 2007;90:15–20.
 155. Fischer-Rasmussen W, Kjaer SK, Dahl C, Asping U. Ginger treatment of hyperemesis gravidarum. *Eur J Obstet Gynecol Reprod Biol* 1991;38:19–24.
 156. Portnoi G, Chng LA, Karimi-Tabesh L, et al. Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. *Am J Obstet Gynecol* 2003;189:1374–1377.
 157. Quinlan JD, Hill DA. Nausea and vomiting of pregnancy. *Am Fam Physician* 2003;68:121–128.
 158. Smith C, Crowther C, Willson K, et al. A randomized controlled trial of ginger to treat nausea and vomiting in pregnancy. *Obstet Gynecol* 2004;103:639–645.
 159. Sripramote M, Lekhyananda N. A randomized comparison of ginger and vitamin B6 in the treatment of nausea and vomiting of pregnancy. *J Med Assoc Thai* 2003;86:846–853.
 160. Vutyavanich T, Kraissarin T, Ruangsri R. Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. *Obstet Gynecol* 2001;97:577–582.
 161. Westfall RE. Use of anti-emetic herbs in pregnancy: women's choices, and the question of safety and efficacy. *Complement Ther Nurs Midwifery* 2004;10:30–36.
 162. Willetts KE, Ekangaki A, Eden JA. Effect of a ginger extract on pregnancy-induced nausea: a randomized controlled trial. *Aust N Z J Obstet Gynaecol* 2003;43:139–144.
 163. Dupuis LL, Nathan PC. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. *Paediatr Drugs* 2003;5:597–613.
 164. Kozletz RL, Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. *Clin Gastroenterol Hepatol* 2004;2:957–967.
 165. Mahesh R, Perumal RV, Pandi PV. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. *Pharmazie* 2005;60:83–96.
 166. Manusirivithaya S, Sripramote M, Tangjitgamol S, et al. Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. *Int J Gynecol Cancer* 2004;14:1063–1069.
 167. Meyer K, Schwartz J, Crater D, et al. Zingiber officinale (ginger) used to prevent 8-Mop associated nausea. *Dermatol Nurs* 1995;7:242–244.
 168. Nordeng H, Havnen GC. Use of herbal drugs in pregnancy: a survey among 400 Norwegian women. *Pharmacoepidemiol Drug Saf* 2004;13:371–380.
 169. Pillai AK, Sharma KK, Gupta YK, et al. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. *Pediatr Blood Cancer* 2011;56:234–238.
 170. Zick SM, Ruffin MT, Lee J, et al. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. *Support Care Cancer* 2009;17:563–572.
 171. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. *Br J Anaesth* 2000;84:367–371.
 172. Kang SC, Lee CM, Choi H, et al. Evaluation of oriental medicinal herbs for estrogenic and antiproliferative activities. *Phytother Res* 2006;20:1017–1019.
 173. Young HY, Liao JC, Chang YS, et al. Synergistic effect of ginger and nifedipine on human platelet aggregation: a study in hypertensive patients and normal volunteers. *Am J Chin Med* 2006;34:545–551.
 174. Barton DL, Soori GS, Bauer BA, et al. Pilot study of *Panax quinquefolius* (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. *Support Care Cancer* 2010;18:179–187.
 175. Kim JH, Park CY, Lee SJ. Effects of sun ginseng on subjective quality of life in cancer patients: a double-blind, placebo-controlled pilot trial. *J Clin Pharm Ther* 2006;31:331–334.
 176. McElhaneey JE, Goel V, Toane B, et al. Efficacy of COLD-IX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo controlled trial. *J Altern Complement Med* 2006;12:153–157.
 177. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. *Drug Saf* 2002;25:323–344.
 178. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. *Cancer Prev Res (Phila Pa)* 2009;2:931–941.

179. Sun CL, Yuan JM, Koh WP, et al. Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. *Carcinogenesis* 2006;27:1301–1309.
180. Nagano J, Kono S, Preston DL, et al. A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan). *Cancer Causes Control* 2001;12:501–508.
181. Setiawan VW, Zhang ZF, Yu GP, et al. Protective effect of green tea on the risks of chronic gastritis and stomach cancer. *Int J Cancer* 2001;92:600–604.
182. Tsubono Y, Nishino Y, Komatsu S, et al. Green tea and the risk of gastric cancer in Japan. *N Engl J Med* 2001;344:632–636.
183. Nakachi K, Suemasu K, Suga K, et al. Influence of drinking green tea on breast cancer malignancy among Japanese patients. *Jpn J Cancer Res* 1998;89:254–261.
184. Imai K, Suga K, Nakachi K. Cancer-preventive effects of drinking green tea among a Japanese population. *Prev Med* 1997;26:769–775.
185. Kurahashi N, Sasazuki S, Iwasaki M, et al. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. *Am J Epidemiol* 2008;167:71–77.
186. Yu GP, Hsieh CC, Wang LY, et al. Green-tea consumption and risk of stomach cancer: a population-based case-control study in Shanghai, China. *Cancer Causes Control* 1995;6:532–538.
187. Gao YT, McLaughlin JK, Blot WJ, et al. Reduced risk of esophageal cancer associated with green tea consumption. *J Natl Cancer Inst* 1994;86:855–858.
188. Ji BT, Chow WH, Hsing AW, et al. Green tea consumption and the risk of pancreatic and colorectal cancers. *Int J Cancer* 1997;70:255–258.
189. Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. *Cancer Res* 2006;66:1234–1240.
190. McLarty J, Bigelow RL, Smith M, et al. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. *Cancer Prev Res (Phila Pa)* 2009;2:673–682.
191. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. *J Natl Cancer Inst* 1999;91:317–331.
192. Kirsh VA, Mayne ST, Peters U, et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:92–98.
193. Kodama N, Komuta K, Nanba H. Can Maitake MD-fraction aid cancer patients? *Altern Med Rev* 2002;7:236–239.
194. Deng G, Lin H, Seidman A, et al. A phase I/II trial of a polysaccharide extract from *Grifola frondosa* (Maitake mushroom) in breast cancer patients: immunological effects. *J Cancer Res Clin Oncol* 2009;135:1215–1221.
195. Styczynski J, Wysocki M. Alternative medicine remedies might stimulate viability of leukemic cells. *Pediatr Blood Cancer* 2006;46:94–98.
196. Cheung CW, Gibbons N, Johnson DW, et al. Silibinin—a promising new treatment for cancer. *Anticancer Agents Med Chem* 2010;10:186–195.
197. Kleijnen J, Knipschild P. Mistletoe treatment for cancer: review of controlled trials in humans. *Phytotherapy* 1994;1:255–260.
198. Grossarth-Maticke R, Kiene H, Baumgartner SM, et al. Use of iscador, an extract of European mistletoe (*Viscum album*), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. *Altern Ther Health Med* 2001;7:57–66.
199. Lenartz D, Schierholz JM, Menzel J. Influence of complementary mistletoe lectin therapy in the treatment of malignant glioma. *Zeitschrift Onkol* 1999;31:44.
200. Schaefermeyer G, Schaefermeyer H. Treatment of pancreatic cancer with *Viscum album* (iscador): a retrospective study of 292 patients 1986–1996. *Comp Ther Med* 1998;6:172–177.
201. McNamee D. Mistletoe extract ineffective in melanoma. *Lancet* 1999;354:1101.
202. Grossarth-Maticke R, Ziegler R. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (iscador): a re-analysis. *Eur J Med Res* 2006;11:485–495.
203. Semiglasov VF, Stepula VV, Dudov A, et al. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. *Anticancer Res* 2004;24:1293–1302.
204. Augustsson K, Michaud DS, Rimm EB, et al. A prospective study of intake of fish and marine fatty acids and prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2003;12:64–67.
205. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. *Pharmacol Ther* 1999;83:217–244.
206. de Deckere EA. Possible beneficial effect of fish and fish N-3 polyunsaturated fatty acids in breast and colorectal cancer. *Eur J Cancer Prev* 1999;8:213–221.
207. Caygill CP, Hill MJ. Fish, N-3 fatty acids and human colorectal and breast cancer mortality. *Eur J Cancer Prev* 1995;4:329–332.
208. Norrish AE, Skeaff CM, Arribas GL, et al. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. *Br J Cancer* 1999;81:1238–1242.
209. Klein V, Chajes V, Germain E, et al. Low alpha-linolenic acid content of adipose breast tissue is associated with an increased risk of breast cancer. *Eur J Cancer* 2000;36:335–340.
210. Terry P, Lichtenstein P, Feychting M, et al. Fatty fish consumption and risk of prostate cancer. *Lancet* 2001;357:1764–1766.
211. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. *J Clin Oncol* 2003;21:129–134.
212. Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. *Gut* 2003;52:1479–1486.
213. Bays HE. Safety considerations with omega-3 fatty acid therapy. *Am J Cardiol* 2007;99:35C–43C.
214. Gao Y, Zhou S, Jiang W, et al. Effects of ganopoly (a *Ganoderma lucidum* polysaccharide extract) on the immune functions in advanced-stage cancer patients. *Immunol Invest* 2003;32:201–215.
215. Gao Y, Tang W, Dai X, et al. Effects of water-soluble *Ganoderma lucidum* polysaccharides on the immune functions of patients with advanced lung cancer. *J Med Food* 2005;8:159–168.
216. Tao J, Feng KY. Experimental and clinical studies on inhibitory effect of *Ganoderma lucidum* on platelet aggregation. *J Tongji Med Univ* 1990;10:240–243.
217. Truelsen T, Gronbaek M, Schnohr P, et al. Intake of beer, wine, and spirits and risk of stroke: the Copenhagen City Heart Study. *Stroke* 1998;29:2467–2472.
218. Gronbaek M, Deis A, Sorensen TI, et al. Mortality associated with moderate intakes of wine, beer, or spirits. *BMJ* 1995;310:1165–1169.
219. Guerrero RF, Garcia-Parrilla MC, Puertas B, et al. Wine, resveratrol and health: a review. *Nat Prod Commun* 2009;4:635–658.
220. Le Corre L, Chalabi N, Delort L, et al. Resveratrol and breast cancer chemoprevention: molecular mechanisms. *Mol Nutr Food Res* 2005;49:462–471.
221. Ramsey TL, Risinger KE, Jernigan SC, et al. Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner. *Endocrinology* 2004;145:149–160.
222. Ackermann S, Hiller S, Osswald H, et al. 17beta-Estradiol modulates apoptosis in pancreatic beta-cells by specific involvement of the sulfonylurea receptor (SUR) isoform SUR1. *J Biol Chem* 2009;284:4905–4913.
223. Wietzke JA, Welsh J. Phytoestrogen regulation of a vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells. *J Steroid Biochem Mol Biol* 2003;84:149–157.
224. Fukui M, Yamabe N, Zhu BT. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. *Eur J Cancer* 2010;46:1882–1891.
225. Piver B, Berthou F, Dreano Y, et al. Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. *Life Sci* 2003;73:1199–1213.
226. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA* 1996;276:1957–1963.
227. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. *Br J Urol* 1998;81:730–734.
228. Combs GF Jr, Clark LC, Turnbull BW. An analysis of cancer prevention by selenium. *Biofactors* 2001;14:153–159.
229. Combs GF Jr. Status of selenium in prostate cancer prevention. *Br J Cancer* 2004;91:195–199.
230. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. *BJU Int* 2003;91:608–612.
231. Duffield-Lillico AJ, Slate EH, Reid ME, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. *J Natl Cancer Inst* 2003;95:1477–1481.
232. Finley JW. Reduction of cancer risk by consumption of selenium-enriched plants: enrichment of broccoli with selenium increases the anticarcinogenic properties of broccoli. *J Med Food* 2003;6:19–26.
233. Huff J. Re: selenium supplementation and secondary prevention of non-melanoma skin cancer in a randomized trial. *J Natl Cancer Inst* 2004;96:333–334.
234. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the selenium and vitamin E cancer prevention trial. *World J Urol* 2003;21:21–27.
235. Klein EA, Lippman SM, Thompson IM, et al. The selenium and vitamin E cancer prevention trial. *World J Urol* 2003;21:21–27.
236. Klein EA. Clinical models for testing chemopreventive agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial. *Recent Results Cancer Res* 2003;163:212–225.
237. Moyad MA. Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? *Urology* 2002;59:9–19.
238. Reid ME, Duffield-Lillico AJ, Garland L, et al. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. *Cancer Epidemiol Biomarkers Prev* 2002;11:1285–1291.
239. Vinceti M, Malagoli C, Bergomi M, et al. Correspondence re: Duffield-Lillico et al., baseline characteristics and the effect of selenium supplementation on

- cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. 11: 630-639, 2002. *Cancer Epidemiol Biomarkers Prev* 2003;12:77.
240. Whanger PD. Selenium and its relationship to cancer: an update. *Br J Nutr* 2004;91:11-28.
 241. Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. *J Natl Cancer Inst* 2004;96:696-703.
 242. Hartman TJ, Albanes D, Pietinen P, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. *Cancer Epidemiol Biomarkers Prev* 1998;7:335-340.
 243. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. *Cancer Epidemiol Biomarkers Prev* 2002;11:630-639.
 244. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. *J Clin Oncol* 2000;18:1068-1074.
 245. Shu XO, Zheng Y, Cai H, et al. Soy food intake and breast cancer survival. *JAMA* 2009;302:2437-2443.
 246. Guha N, Kwan ML, Quesenberry CP Jr, et al. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. *Breast Cancer Res Treat* 2009;118:395-405.
 247. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res* 2008;14:4491-4499.
 248. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. *Arch Pharm (Weinheim)* 2010;343:489-499.
 249. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. *BMC Complement Altern Med* 2006;6:10.
 250. Donatus IA, Sardjoko, Vermeulen NP. Cytotoxic and cytoprotective activities of curcumin. Effects on paracetamol-induced cytotoxicity, lipid peroxidation and glutathione depletion in rat hepatocytes. *Biochem Pharmacol* 1990;39:1869-1875.
 251. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. *J Clin Oncol* 2009;27:504-510.
 252. The Alpha-Tocopherol and Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med* 1994;330:1029-1035.
 253. Creagan ET, Moertel CG, O'Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. *N Engl J Med* 1979;301:687-690.
 254. Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. *N Engl J Med* 1985;312:137-141.
 255. Goodwin PJ, Ennis M, Pritchard KI, et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. *J Clin Oncol* 2009;27:3757-3763.
 256. Mezawa H, Sugiura T, Watanabe M, et al. Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study. *BMC Cancer* 2010;10:347.
 257. Freedman DM, Looker AC, Chang SC, et al. Prospective study of serum vitamin D and cancer mortality in the United States. *J Natl Cancer Inst* 2007;99:1594-1602.
 258. Bardia A, Tleyeh IM, Cerhan JR, et al. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. *Mayo Clin Proc* 2008;83:23-34.
 259. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA* 2007;297:842-857.
 260. Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst Rev* 2008;(2):CD007176.
 261. Miller ER III, Pastor-Barrisuro R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005;142:37-46.
 262. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. *Neurology* 2005;64:26-31.
 263. Argyriou AA, Chroni E, Koutras A, et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. *Support Care Cancer* 2006;14:1134-1140.
 264. Argyriou AA, Chroni E, Koutras A, et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. *J Pain Symptom Manage* 2006;32:237-244.
 265. Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. *J Clin Oncol* 2003;21:927-931.
 266. Pace A, Giannarelli D, Galie E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. *Neurology* 2010;74:762-766.
 267. Dundee JW, Chahly RC, Fitzpatrick KT, et al. Acupuncture prophylaxis of cancer chemotherapy-induced sickness. *J R Soc Med* 1989;82:268-271.
 268. Williams CJ, Price H, Sergiou K. A randomized trial of acupressure for chemotherapy-induced emesis. *Proc Annu Meet Am Soc Clin Oncol* 1992;11:A1394.
 269. Wilkinson S, Aldridge J, Salmon I, et al. An evaluation of aromatherapy massage in palliative care. *Palliat Med* 1999;13:409-417.
 270. Kolcaba K, Fox C. The effects of guided imagery on comfort of women with early stage breast cancer undergoing radiation therapy. *Oncol Nurs Forum* 1999;26:67-72.
 271. Comer J, Cawley N, Hildebrand S. An evaluation of the use of massage and essential oils on the well-being of cancer patients. *Int J Palliat Nurs* 1995;1:67-73.
 272. Ferrell-Torrey AT, Glick OJ. The use of therapeutic massage as a nursing intervention to modify anxiety and the perception of cancer pain. *Cancer Nurs* 1993;16:93-101.
 273. Risberg T, Wist E, Kaasa S, et al. Spiritual healing among Norwegian hospitalized cancer patients and patients' religious needs and preferences of pastoral services. *Eur J Cancer* 1996;32A:274-281.
 274. Fellowes D, Gambles M, Lockhart-Wood K. Reflexology for symptom relief in patients with cancer. *Cochrane Database Syst Rev* 2004;2:CD002287.
 275. Olson K, Hanson J. Using Reiki to manage pain: a preliminary report. *Cancer Prev Control* 1997;1:108-113.
 276. Giasson M, Bouchard L. Effect of therapeutic touch on the well-being of persons with terminal cancer. *J Holist Nurs* 1998;16:383-398.
 277. Baider L, Uziely B, De Nour AK. Progressive muscle relaxation and guided imagery in cancer patients. *Gen Hosp Psychiatry* 1994;16:340-347.
 278. Sloman R. Relaxation and the relief of cancer pain. *Nurs Clin North Am* 1995;30:697-709.
 279. Moskowitz L. Psychological management of postsurgical pain and patient adherence. *Hand Clin* 1996;12:129-137.
 280. Ross MC, Bohannon AS, Davis DC, et al. The effects of a short-term exercise program on movement, pain, and mood in the elderly. Results of a pilot study. *J Holist Nurs* 1999;17:139-147.
 281. Spiegel D, Moore R. Imagery and hypnosis in the treatment of cancer patients. *Oncology (Williston Park)* 1997;11:1179-1189.
 282. Walker LG, Walker MB, Ogston K, et al. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. *Br J Cancer* 1999;80:262-268.
 283. Wallace KG. Analysis of recent literature concerning relaxation and imagery interventions for cancer pain. *Cancer Nurs* 1997;20:79-87.
 284. Richardson MA, Post-White J, Grimm EA, et al. Coping, life attitudes, and immune responses to imagery and group support after breast cancer treatment. *Altern Ther Health Med* 1997;3:62-70.
 285. Turner-Cobb JM, Sephton SE, Koopman C, et al. Social support and salivary cortisol in women with metastatic breast cancer. *Psychosom Med* 2000;62:337-345.
 286. Coker KH. Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. *Semin Urol Oncol* 1999;17:111-118.
 287. Massion AO, Teas J, Hebert JR, et al. Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data. *Med Hypotheses* 1995;44:39-46.
 288. Arakawa S. Relaxation to reduce nausea, vomiting, and anxiety induced by chemotherapy in Japanese patients. *Cancer Nurs* 1997;20:342-349.
 289. Manyande A, Berg S, Gettins D, et al. Preoperative rehearsal of active coping imagery influences subjective and hormonal responses to abdominal surgery. *Psychosom Med* 1995;57:177-182.
 290. Syrjala KL, Chapko ME. Evidence for a biopsychosocial model of cancer treatment-related pain. *Pain* 1995;61:69-79.
 291. Troesch LM, Rodehaver CB, Delaney EA, et al. The influence of guided imagery on chemotherapy-related nausea and vomiting. *Oncol Nurs Forum* 1993;20:1179-1185.
 292. Fawzy FI, Fawzy NW, Arndt LA, et al. Critical review of psychosocial interventions in cancer care. *Arch Gen Psychiatry* 1995;52:100-113.
 293. Helgeson VS, Cohen S, Schulz R, et al. Group support interventions for women with breast cancer: who benefits from what? *Health Psychol* 2000;19:107-114.
 294. Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized outcome study. *Arch Gen Psychiatry* 1981;38:527-533.
 295. Fawzy FI, Cousins N, Fawzy NW, et al. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. *Arch Gen Psychiatry* 1990;47:720-725.
 296. Gordon JS. Mind-body medicine and cancer. *Hematol Oncol Clin North Am* 2008;22:683-708.
 297. Helgeson VS, Cohen S, Schulz R, et al. Education and peer discussion group interventions and adjustment to breast cancer. *Arch Gen Psychiatry* 1999;56:340-347.
 298. Richardson JL, Shelton DR, Krailo M, et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. *J Clin Oncol* 1990;8:356-364.
 299. Bower JE, Woolery A, Sternlieb B, et al. Yoga for cancer patients and survivors. *Cancer Control* 2005;12:165-171.
 300. Chandwani KD, Thornton B, Perkins GH, et al. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. *J Soc Integr Oncol* 2010;8:43-55.

301. Cohen L, Warneke C, Fouladi RT, et al. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. *Cancer* 2004;100:2253–2260.
302. Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. *JAMA* 1996;276:313–318.
303. Zeltzer LK, Dolgin MJ, LeBaron S, et al. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. *Pediatrics* 1991;88:34–42.
304. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. *N Engl J Med* 1982;307:1476–1480.
305. Faymonville ME, Mambourg PH, Joris J, et al. Psychological approaches during conscious sedation. Hypnosis versus stress reducing strategies: a prospective randomized study. *Pain* 1997;73:361–367.
306. Lang EV, Benotsch EG, Fick LJ, et al. Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. *Lancet* 2000;355:1486–1490.
307. Lang EV, Berbaum KS, Faintuch S, et al. Adjunctive self-hypnotic relaxation for outpatient medical procedures: a prospective randomized trial with women undergoing large core breast biopsy. *Pain* 2006;126:155–164.
308. Montgomery GH, Bovbjerg DH, Schnur JB, et al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. *J Natl Cancer Inst* 2007;99:1304–1312.
309. Devine EC, Westlake SK. The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies. *Oncol Nurs Forum* 1995;22:1369–1381.
310. Newell SA, Sanson-Fisher RW, Savolainen NJ. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. *J Natl Cancer Inst* 2002;94:558–584.
311. Ernst E, Pittler MH, Wider B, et al. Mind-body therapies: are the trial data getting stronger? *Altern Ther Health Med* 2007;13:62–64.
312. Ahles TA, Tope DM, Pinkson B, et al. Massage therapy for patients undergoing autologous bone marrow transplantation. *J Pain Symptom Manage* 1999;18:157–163.
313. Wyatt G, Sikorskii A, Rahbar MH, et al. Health-related quality-of-life outcomes: a reflexology trial with patients with advanced-stage breast cancer. *Oncol Nurs Forum* 2012;39:568–577.
314. Fernández-lao C, Cantarero-villanueva I, Díaz-rodríguez L, et al. Attitudes towards massage modify effects of manual therapy in breast cancer survivors: a randomised clinical trial with crossover design. *Eur J Cancer Care (Engl)* 2012;21:233–241.
315. Ernst E. The safety of massage therapy. *Rheumatology (Oxford)* 2003;42:1101–1106.
316. Myers CD, Walton T, Small BJ. The value of massage therapy in cancer care. *Hematol Oncol Clin North Am* 2008;22:649–660.
317. World Health Organization. *Traditional Medicine Strategy 2002–2005*. Geneva: WHO; 2002.
318. Helms JM. *Acupuncture Energetics: A Clinical Approach for Physicians*. Berkeley: Medical Acupuncture Publishers; 1997.
319. Mittleman E, Gaynor JS. A brief overview of the analgesic and immunologic effects of acupuncture in domestic animals. *J Am Vet Med Assoc* 2000;217:1201–1205.
320. Altman S. *Techniques and Instrumentation, Electroacupuncture. Veterinary Acupuncture—Ancient Art to Modern Medicine*. St. Louis: Mosby; 1994.
321. NIH Consensus Conference. Acupuncture. *JAMA* 1998;280:1518–1524.
322. Alimi D, Rubino C, Pichard-Leandri E, et al. Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial. *J Clin Oncol* 2003;21:4120–4126.
323. Park J, Linde K, Manheimer E, et al. The status and future of acupuncture clinical research. *J Altern Complement Med* 2008;14:871–881.
324. Jedel E. Acupuncture in xerostomia—a systematic review. *J Oral Rehabil* 2005;32:392–396.
325. Lee MS, Kim KH, Choi SM, et al. Acupuncture for treating hot flashes in breast cancer patients: a systematic review. *Breast Cancer Res Treat* 2009;115:497–503.
326. Crew KD, Capodice JL, Greenlee H, et al. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. *J Cancer Surviv* 2007;1:283–291.
327. Crew KD, Capodice JL, Greenlee H, et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. *J Clin Oncol* 2010;28:1154–1160.
328. Filshie J, Hester J. Guidelines for providing acupuncture treatment for cancer patients—a peer-reviewed sample policy document. *Acupunct Med* 2006;24:172–182.
329. Lewith G, Berman B, Cummings M, et al. Systematic review of systematic reviews of acupuncture published 1996–2005. *Clin Med* 2006;6:623–625.
330. Ernst E, White AR. Prospective studies of the safety of acupuncture: a systematic review. *Am J Med* 2001;110:481–485.
331. Filshie J. Safety aspects of acupuncture in palliative care. *Acupunct Med* 2001;19:117–122.